IR Biosciences Holdings Inc. (IRBS)
IR Biosciences Holdings Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Scottsdale, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $128,122. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of 0.0%. Its beta of 5.01 implies it has historically moved more than the broad market.
IR BioSciences Holdings, Inc. is a U.S.-based, early-stage biotechnology firm. Through its subsidiary, ImmuneRegen BioSciences, Inc., it concentrates on researching and developing therapies for significant health challenges, including pulmonary fibrosis, influenza infections, and neutropenia caused by radiation. The company is also actively developing Homspera and its derivatives, Radilex and Viprovex. These compounds are designed to stimulate human stem cells, enhance immune system responses, offer anti-infective properties, serve as vaccine adjuvants, and promote wound healing. Founded in 1999, IR BioSciences Holdings, Inc. maintains its headquarters in Scottsdale, Arizona.
IR Biosciences Holdings Inc. is most often compared with the following Healthcare names: